Soleno Therapeutics, Inc. (SLNO) Earnings Call Analysis

NASDAQ · Unknown · Unknown

Earnings Reports

• Soleno Therapeutics (SLNO) Q4 2025: 40% Sequential Revenue Surge Anchors PWS Franchise Expansion
  February 26, 2026
• Soleno Therapeutics (SLNO) Q3 2025: Revenue Doubles as VICAT-XR Adoption Hits 764 Patients
  November 05, 2025
• Soleno Therapeutics (SLNO) Q2 2025: 646 Patient Starts Signal Launch Outperformance and Expanding Payer Access
  August 07, 2025
• Salino Therapeutics (SLNO) Q1 2025: 268 Start Forms Signal Early Vicat XR Launch Momentum
  July 04, 2025

Browse all companies